



## LEERINK SWANN

### Conquering Cancer with Novel Therapeutics: Roundtable Conference Friday, May 9, 2008

#### Final Agenda

The Grand Hyatt New York  
109 East 42<sup>nd</sup> Street at Grand Central Station

Phone (212) 883-1234  
Fax (212) 697-3772

| <b>Time</b>  | <b>All meetings will be held in the Broadway Room, Conference Level</b>  |
|--------------|--|
| 7:45-8:20am  | Conference Registration and Continental Breakfast (Broadway Room Foyer, Conference Level)  |
| 8:20-8:35    | <b>Welcome Remarks</b><br>Howard Liang, Ph.D., Analyst, Biotechnology, Leerink Swann   |
| 8:35-9:20    | <b>Expert Panel: Novel Targeted Agents for Cancer-What Target and Which Pathway?</b><br><i>Company Representatives:</i><br>Tim Clackson, Ph.D., Chief Scientific Officer, ARIAD Pharmaceuticals, Inc.<br>Thomas C. K. Chan, Ph.D., Senior Vice President, Discovery and Preclinical Development, ArQule, Inc.<br>Kevin Koch, Chief Scientific Officer, Array BioPharma, Inc.<br>Harren Jhoti, Chief Executive Officer, Astex Therapeutics Ltd.<br>Murray Robinson, Ph.D., Senior Vice President, Oncology, AVEO Pharmaceuticals, Inc.<br><i>MEDACorp Opinion Leader:</i> Neal Rosen, M.D. Ph.D.<br><i>Moderator:</i> Howard Liang, Ph.D., Analyst, Biotechnology, Leerink Swann and Jessica Barnes, Ph.D., Senior Associate, Leerink Swann |
| 9:20-9:40    | <b>Array BioPharma, Inc.</b><br>Robert Conway, Chief Executive Officer   |
| 9:40-10:00   | <b>ArQule, Inc.</b><br>Peter Lawrence, Chief Operating Officer   |
| 10:00-10:20  | <b>ARIAD Pharmaceuticals, Inc.</b><br>Tim Clackson, Ph.D., Chief Scientific Officer  |
| 10:20-10:40  | <b>AVEO Pharmaceuticals, Inc.</b><br>Tuan Ha-Ngoc, President and Chief Executive Officer   |
| 10:40-10:50  | <b>Morning Break</b>   |
| 10:50-11:10  | <b>Proteolix, Inc.</b><br>Susan Molineaux, Ph.D., Chief Executive Officer  |
| 11:10-11:30  | <b>Kosan Biosciences Incorporated</b><br>Jane Green, Ph.D., Vice President, Corporate Communications   |
| 11:30-Noon   | <b>Lunch Break (a buffet lunch is available in the Broadway Room Foyer, Conference Level)</b>  |
| Noon-12:45pm | <b>Expert Panel: New Developments in Liquid Tumors-Focusing on Multiple Myeloma and Lymphomas</b><br><i>Company Representatives:</i><br>Perry Karsen, Senior Vice President, Business Development, Celgene Corporation<br>Alison Hannah, Acting Chief Medical Officer, Kosan Biosciences Incorporated<br>Susan Molineaux, Ph.D., Chief Executive Officer, Proteolix, Inc.<br><i>MEDACorp Opinion Leaders:</i> Francine Foss, M.D. and David Vesole, M.D., Ph.D., F.A.C.P.<br><i>Moderator:</i> Howard Liang, Ph.D., Analyst, Biotechnology, Leerink Swann  |
| 12:45-12:55  | <b>Afternoon Break</b>   |
| 12:55-1:15   | <b>Cougar Biotechnology, Inc.</b><br>Alan Auerbach, President and Chief Executive Officer  |
| 1:15-1:35    | <b>Cell Genesys, Inc.</b><br>Robert Dow, Senior Vice President and Chief Medical Officer   |
| 1:35-1:55    | <b>Poniard Pharmaceuticals, Inc.</b><br>Jerry McMahon, Chairman and Chief Executive Officer  |
| 1:55-2:15    | <b>Medivation, Inc.</b><br>David Hung, President and Chief Executive Officer   |
| 2:15-3:00    | <b>Expert Panel: New Developments in Solid Tumors-Focusing on Prostate and Lung Cancers</b><br><i>Company Representatives:</i><br>Robert Dow, Senior Vice President and Chief Medical Officer, Cell Genesys, Inc.<br>Alan Auerbach, President and Chief Executive Officer, Cougar Biotechnology, Inc.<br>David Hung, President and Chief Executive Officer, Medivation, Inc.<br>Jerry McMahon, Chairman and Chief Executive Officer, Poniard Pharmaceuticals, Inc.<br><i>MEDACorp Opinion Leaders:</i> Robert Dreicer, M.D., M.S., F.A.C.P. and Vince Miller, M.D.<br><i>Moderator:</i> Howard Liang, Ph.D., Analyst, Biotechnology, Leerink Swann and William Tanner, Ph.D., Analyst Biotechnology, Leerink Swann                         |

**\*Private 1-1 meetings with MEDACorp Opinion Leaders and Company Management will be held throughout the day. You must register for these meetings at the registration desk.**